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GPCRs represent the largest class of signaling receptors in the genome, as well as the protein family most frequently tar-geted by therapeutic drugs (Fig. 1). GPCRs respond to vari-
ous ligands, from protons to biogenic amines to lipids to chemokine 
proteins, and are involved in biological phenomena varying from cell 
division to bronchial relaxation to heart rate and blood pressure con-
trol, in addition to learning, memory, and cognition. Their attractive-
ness for drug discovery reflects the importance of the signals they 
transduce and the extracellular accessibility of their binding sites. 
Structural determination of almost 40 GPCRs in the last decade has 
revealed them to be well suited for small-molecule recognition—a 
post hoc explanation for their preponderance among drug targets.
Most GPCR drugs were discovered by combining classical 
medicinal chemistry with organ and cell-based pharmacology, 
decades before their targets were classified into a single family or 
even defined as true molecular entities1 (Fig. 1). It has been esti-
mated that 70% of GPCR drugs are analogs derived from the endog-
enous ligands of the receptors2; although this is not strictly true, the 
small chemical repertoire of early drug discovery, and the inability to 
counterscreen for specificity, ensured that many of the GPCR drugs 
resembled one another and were promiscuous. Whereas the result-
ing polypharmacology has sometimes contributed to efficacy3,4, the 
lack of specificity of these older drugs has limited their usefulness as 
tools and has contributed to their side effects.
In the last decade, three discoveries have motivated the search 
for new GPCR chemotypes. First, it has become clear that GPCRs 
couple not only to their eponymous G proteins, but to other effectors 
as well, activating orthogonal pathways5 (Fig. 2). This has inspired 
campaigns to find ‘biased’ agonists that preferentially activate one 
pathway over another. Second, the determination of pharmaco-
logically relevant GPCR crystal structures6 has revealed the binding 
sites of allosteric modulators and suggested new potential allosteric 
sites. Ligands that bind to these sites can either negatively or posi-
tively modulate endogenous transmitters with or without an intrin-
sic signaling effect of their own (Fig. 3). Third, the GPCR structures 
have enabled structure-based discovery and optimization of new 
ligands. Together, these developments have supported a renaissance 
in GPCR pharmacology and drug discovery.
Here we consider new approaches to finding tool molecules 
and therapeutic leads for GPCRs. These methods include physical 
assays that can interrogate most of the ~350 pharmacologically rel-
evant GPCRs, including orphans, as well as structure-based dock-
ing screens that interrogate large compound libraries. We will focus 
more on the structure-guided approaches, as these are potentially 
scalable for use by a wide community and have received less atten-
tion among pharmacologists. A key contention of this Perspective 
is that the novel chemotypes discovered by these new technologies 
will often confer new biology, even against heavily interrogated tar-
gets. Although there is no single physical reason why this should be 
true, novel chemotypes may interact to stabilize one of the mani-
fold of conformations available to GPCRs7,8 in unique ways. This in 
turn can activate one of the multiple pathways downstream of the 
receptor with a specificity not previously explored by endogenous 
or synthetic ligands.
Structure-based docking screens
Molecular docking virtually screens large libraries of compounds 
for their fit into a receptor pocket. About 107 complexes are sam-
pled, including thousands of orientations and conformations for 
each library compound, occasionally along with several snapshots 
of low-energy receptor conformations. Screens of several million 
molecules are common, and between 1013 to 1014 complexes may be 
sampled and scored. Docking scoring functions evaluate polar and 
nonpolar complementarity, steric fit, and solvation, among other 
terms. On an academic cluster, such a screen might be completed in 
several days of elapsed time (hundreds of core days).
This speed comes at the expense of accuracy, and docking scor-
ing functions make grave approximations. The technique is unable 
to calculate binding affinities accurately, reliably rank order among 
high-scoring molecules9, or typically differentiate agonists from 
antagonists. What a docking screen can hope to do is distinguish 
plausible ligands from the vast number of library molecules that will 
not bind (decoys). When drawn from commercially available mole-
cules or from an in-house library, failure is cheap, and the enterprise 
is worthwhile, as long as new and interesting molecules are found, 
notwithstanding the false-negatives.
A driver of this method has been the secular expansion of the 
docking libraries. These libraries reflect the integrated interests of the 
community over time, and are composed of molecules resembling 
metabolites, natural products, and drugs. Thus, docked molecules 
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Although a plurality of drugs target G-protein-coupled receptors (GPCRs), most have emerged from classical medicinal chem-
istry and pharmacology programs and resemble one another structurally and functionally. Though effective, these drugs are 
often promiscuous. With the realization that GPCRs signal via multiple pathways, and with the emergence of crystal structures 
for this family of proteins, there is an opportunity to target GPCRs with new chemotypes and confer new signaling modalities. 
We consider structure-based and physical screening methods that have led to the discovery of new reagents, focusing particu-
larly on the former. We illustrate their use against previously untargeted or orphan GPCRs, against allosteric sites, and against 
classical orthosteric sites that selectively activate one downstream pathway over others. The ligands that emerge are often 
chemically novel, which can lead to new biological effects. 
are not only readily acquired, but also typically far more bio-like than 
would be expected from a truly diverse, random library10. Over the last 
25 years, the size of docking libraries of commercially available com-
pounds have doubled every 2.5 years, and now approach 10 million 
accessible ‘lead-like’ molecules with favorable physical properties.
Both docking programs and their libraries are available to the 
community, many for free (for example, http://blaster.docking.org 
and http://zinc15.docking.org; see ref. 9). Admittedly, there remains 
an art to docking, including visual interrogation of top-ranking mol-
ecules from the library and hit-picking parties9 that expose them to 
teams of medicinal chemists, structural biologists, and pharmacolo-
gists. Still, investigators can launch large library campaigns using 
community-available programs, libraries, and public access compu-
tational clusters from their desktops.
GPCRs as templates for docking screens
In the early 2000s, hit rates against soluble proteins in prospective, 
unbiased docking screens ran between 5%11 and 35%12, with hit 
rate defined as the number of compounds active on testing divided 
by the number physically tested. Occasionally, docking screens of 
receptor-focused libraries could enjoy even higher hit rates13, and 
even then the technique had successes against GPCR homology 
models14. Still, certainly in our hands and especially for general 
library screens, the lower rates of 5–10% were more common, and 
against some targets the method failed entirely (and such outright 
failure can still occur today). Docking campaigns were most suc-
cessful against tightly defined sites such as nuclear hormone recep-
tors15. Encouragingly, the docking predicted structures that typically 
corresponded to the experimental result when co-complexes were 
determined by crystallography11,16–18. Still, with high false positive 
rates, and affinities often in the midmicromolar range, the reliability 
of docking for tool molecule discovery remains questionable.
Docking outcomes often have been better against GPCRs, with 
hit rates regularly above 20% and as high as 73%, and affinities 
occasionally in the sub- and often in the midnanomolar range 
(Table 1). Docking is typically more successful against neurotrans-
mitter GPCRs, with their tighter orthosteric sites, than against pep-
tide- and protein-binding GPCRs, but even against the latter, hit rates 
and affinities have been substantial. Compellingly, these screens have 
found new chemotypes even against well-established receptors. There 
is no single explanation for this improvement, but it may reflect (1) 
the well-formed binding sites of the receptors compared to those 
of soluble receptors; (2) bias in the libraries toward GPCR chemo-
types19; and (3) the incremental improvement in docking methods 
over the last 15 years9, with most of the GPCR docking screens occur-
ring in the last six years. The combination of high hit-rates, high hit 
affinities, and hit novelty supports the pragmatism of structure-based 
screens for new GPCR chemotypes. Remarkably, these new chemo-
types often confer new patterns of GPCR signaling and biology.
Allostery and bias
By convention, the binding sites for endogenous ligands at 
GPCRs have been referred to as orthosteric, whereas binding 
sites that modulate orthosteric ligand activity have been called 


























































Figure 1 | GPCR drugs as a percentage of all drugs, by decade of 
introduction. Total number of drugs introduced (blue); number of drugs 
targeting GPCRs as primary mechanism-of-action targets (green);  
number of non-GPCR drugs that also act on a GPCR at levels higher  
than 1 M (yellow), number of non-GPCR drugs predicted to act on  
GPCRs, with similarity ensemble approach (SEA)-based104 E-values  

























































































































Figure 2 | GPCRs may activate multiple downstream signaling pathways: 
role of biased signaling. (a) Shown are typical pathways modulated 
by G-protein and arrestin ( -arr) biased ligands, which lead to different 
intracellular signaling pathways and distinct in vivo activities. MAPK, 
mitogen-activated protein kinase; cAMP, cyclic AMP. (b) A heat map for 
ligand functional selectivity against the 5HT2B receptor reveals distinct 
ligand-specific patterns. Shown are calculated estimates of bias for 5HT2B 
agonists at downstream targets. Data are from ref. 105, and estimates of 
bias were calculated using the operational model and displayed on a heat 
map. ERK, extracellular signal-regulated kinase; IP, inositol phosphate; NFAT, 
nuclear factor of activated T cells.
Pharmacology/British Pharmacological Society (IUPHAR) defines 
an allosteric site as a “binding site on a receptor macromolecule that 
is nonoverlapping and spatially distinct from, but conformationally 
linked to, the orthosteric binding site.” A functional definition of 
allostery, meanwhile, emphasizes the saturation of the effect, with 
no further modulation seen past a certain concentration of the allos-
teric ligand. It also emphasizes the ‘probe dependence’ of allostery, 
with the same allosteric ligand having different effects on diverse 
orthosteric ligands. A fascinating aspect of allosteric modulators is 
that their actions may be only manifest in the presence of an endog-
enous signaling molecule or an orthosteric drug, whose signaling 
effects they amplify or dampen without a tonic effect of their own. 
The ability of allosteric potentiators to faithfully amplify the spatial 
and temporal aspects of native signaling makes them unique among 
drugs (further reviewed in ref. 7).
GPCRs recognize allosteric ligands at several distinct sites. The 
earliest allosteric modulator characterized was the negative allos-
teric modulator (NAM) sodium acting on the opioid receptor22. 
Since then, sodium has been recognized as a NAM for many fam-
ily members, acting via a conserved pocket on the cytoplasmic 
side of the orthosteric site23,24 (Fig. 3). Following agonist binding, 
G-protein engagement, and receptor activation, the sodium pocket
collapses, relieving the negative allosteric brake on signaling. This
sodium pocket might be targetable by small molecules extending
from the orthosteric site.
Allosteric sites for drug-like molecules have also been character-
ized in GPCRs. In metabotropic glutamate receptors, both positive 
allosteric modulators (PAMs) and NAMs have been designed25. In 
smoothened, functionally allosteric modulators have been observed 
crystallographically in what would be part of the transmembrane 
orthosteric site in other GPCR families26 (Fig. 3). In muscarinic 
receptors, a large open vestibule has been structurally character-
ized on the extracellular side of the orthosteric site27,28, which 
is consistent with the binding of the PAMs and NAMs that have 
emerged from functional studies29. In the M2 receptor, this vestibule 
closes upon formation of a tertiary complex with a PAM and an 
orthosteric agonist (Fig. 3). A spectacular result of recent crystal-
lography, and one case of a large DNA-encoded library screening30, 
is that two other allosteric sites on GPCRs are targetable by small 
molecules: the intracellular region where G protein binds31,32 and an 
intramembrane region on the outer surface of the helical bundle33,34. 
These sites appear conserved among family A GPCRs, suggesting 
that they may be broadly targeted. Admittedly, they are shallower 
than is typical of GPCR orthosteric sites and may be more challeng-
ing for ligand discovery.
Functional selectivity, or signaling bias, also reflects modulation 
of downstream signaling by ligands, here by favoring one of sev-
eral possible pathways. As originally proposed35 and subsequently 
expanded upon36,37, functional selectivity from a chemical biology 
perspective is “the ligand-dependent selectivity for certain signal 
transduction pathways in one and the same receptor.” From a cou-
pling standpoint, functional selectivity could arise via differential 
activation of G-protein signaling (for example, Gi vs. Gs, as for the 
2-adrenergic receptor38) or, more commonly, differential activation 
of -arrestin ( -arr) compared to G-protein signaling5 (Fig. 2a). 
From a structural standpoint, biased signaling reflects the mul-
tiple activated states through which a GPCR can transit that can 
be stabilized by different ligands. There are many possible effectors 
through which GPCRs modulate signaling, including several G 
proteins, -arrs, and kinases, and each may be involved in different 
pathways. Thus, it is conceivable that for some GPCRs, each ligand 
could have a unique signature when multiple effectors are mea-
sured39, and one could imagine ligands with downstream signaling 
signatures tailored for different outcomes. This may be exemplified 
at the 5-HT2B serotonin receptor, against which each ligand may be 
clustered by a signaling signature (Fig. 2b).
Several new tools allow high-resolution interrogation of allosteric 
modulation and functional selectivity, enabling new activity screens. 
A near GPCRome-wide -arr screening platform, PRESTO-Tango40, 
now available via ADDGENE (https://www.addgene.org/kits/roth-
gpcr-presto-tango/), has been used by several labs to determine the 
extent of -arr activation and bias for GPCRs23,41–43. In our own lab, 
the platform has been used to screen for ligands that illuminate the 
function of orphan and understudied GPCRs (oGPCRs)40, such as 
MRGPRX2 (ref. 44).
An approach to discovering allosteric modulators in the absence 
of an orthosteric agonist, which is useful for illuminating oGPCRs, 
involves the overexpression of G proteins in yeast45 and the tun-
ing of their constitutive activity (Fig. 3d). Here we exploited the 
extended ternary complex model, which predicts that overexpres-
sion of GPCRs will potentiate basal GPCR activity. Because yeast G 
proteins interact poorly with mammalian GPCRs, systematic bias 
or crosstalk between endogenous and exogenous G proteins and 
GPCRs is minimized. The enhanced basal activity allows not only 
agonists, but also inverse agonists and allosteric modulators to be 
identified (Fig. 3d). We have used this system to discover initial 
hits for multiple oGPCRs, optimizing them into allosteric chemical 
probes for GPR68 and GPR65.
Several other approaches for interrogating GPCRs, including new 
G-protein and -arr biased chemogenetic tools, have been recently
introduced46,47. New conformationally sensitive -arr sensors have
been reported that may enable the unbiased identification of GPCR
modulators, including small molecules and interacting proteins,
that bias GPCRs toward different states of -arr activation48.
Case studies
From a receptor-centric perspective, new GPCR ligands can confer 
new biology in three ways. First, they can bind to an entirely new 
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Figure 3 | Multiple allosteric sites for GPCRs. (a) Site for the negative 
allosteric modulator (NAM) sodium in prototypical GPCRs, revealing its 
conserved location. The small orange and purple dots represent water 
molecules. (b) The locations of a muscarinic receptor positive allosteric 
modulator (PAM) and an orthosteric ligand. (c) Smoothened, and the 
location of various allosteric ligands for which crystal structures have been 
solved. (d) The elongated pocket defined by these ligands; the arrows 
illustrate sites for candidate Smoothened ligands.
target. Second, they can bind to a new site on an established target, 
allosterically modulating endogenous transmitter or drug signaling. 
Finally, and most surprisingly, they can bind to an established site 
on an established target and confer new biology by biased signaling, 
specifically activating one of multiple GPCR signaling pathways via 
preferential stabilization of one of many activated states (Fig. 2).
New chemistry for new targets
New biology is expected the first time a GPCR is modulated by a drug 
or reagent. Recent examples include the anti-HIV drug maraviroc, 
which targets CCR5; the anti-neoplastic vismodegib, which targets 
Smoothened; and molecules that have deorphanized GPCRs.
Maraviroc and CCR5. CCR5 is a co-receptor for HIV cell entry. 
As CCR5 is a membrane protein, a point of host–pathogen inter-
action, a protein–protein interface (PPI) target, and a receptor for 
which there were no previous drugs, it presented multiple technical 
challenges. A high-throughput screen (HTS) at Pfizer returned hits 
with ligand efficiencies that were substantially higher than the 0.24 
kcal/HAC (heavy atom count) mooted as a bar for most PPI targets49, 
consistent with the general advantages of GPCRs for small-molecule 
recognition. Advancement to maraviroc involved multiple rounds of 
chemical optimization to overcome hERG (human ether-à-go-go-
related gene), a cardiac ion channel and metabolic liabilities. Though 
the crystal structure of the maraviroc–CCR5 complex shows that the 
drug partly overlaps with the orthosteric chemokine site50, its probe 
dependence and its saturable noncompetitive binding functionally 
define it as a CCR5 NAM. Because the series leading to maraviroc 
emerged from target-based HTS, it bears little similarity to biogenic 
molecules, unlike many drugs from the premolecular era.
Vismodegib and Smoothened. Smoothened is a class F (Frizzled) 
GPCR that modulates embryonic development and tissue homeo-
stasis as part of the hedgehog signaling pathway51. Protein mutations 
and epigenetic changes that hyperactivate this pathway are com-
mon in human tumors52. Vismodegib (GDC-0449), described by 
Genentech in 2009 (ref. 53), antagonizes Smoothened54, inhibiting 
hedgehog signaling. Vismodegib was the first drug approved for 
this pathway and is used to treat late-stage basal cell carcinomas. 
Resistance to this drug arises from point mutations in Smoothened 
itself (for example, D473H), which abolish binding while maintain-
ing protein activity54. As revealed by crystallography, substitutions 
at D4736.55 have differential effects on antagonists55, suggesting 
opportunities for structure-based discovery of new molecules that 
avoid this and other resistance mutations56 that rapidly appear upon 
vismodegib treatment57.
GPCR deorphanization. Because the new screening platforms 
(above) do not depend on knowing an agonist or displaceable ligand 
in advance, they have enabled the interrogation of understudied and 
oGPCRs58. Using yeast growth and PRESTO-Tango platforms, mol-
ecules may be screened against oGPCRs without knowing an agonist 
or function in advance. The libraries screened are often composed of 
privileged compounds—drugs and reagents—and hits reveal not only 
starting points for probes, but also previously hidden drug off-targets. 
For instance, a recent large-scale interrogation of oGPCRs by the 
PRESTO-Tango resource revealed that nateglinide, a putatively selec-
tive potassium channel modulator, is a potent agonist of the oGPCR 
MRGPRX4. Similarly, saquinivar—a putatively selective HIV protease 
inhibitor—emerged as a potent agonist of the oGPCR BRB3 (ref. 40).
However, the drugs and reagents that make up the privileged 
library cannot themselves be used to probe oGPCRs biology, as they 
are almost always far more potent at their therapeutic targets. To 
leverage the initial hits for probe development, a combined experi-
mental- and structure-based approach has been adopted. This can 
be illustrated by a deorphanization campaign against GPR68 (also 
known as OGR1)45. In a yeast-based screen, the GABAergic drug 
lorazepam was found to be a GPR68 PAM for protons, fortuitously 
present at higher concentrations in the low pH of the yeast screen. 
Several thousand structural models of GPR68 were calculated and 
prioritized by their ability to dock and highly rank lorazepam in 
comparison to the hundreds of nonbinding decoy drugs from the 
experimental screen. A cycle of docking, model refinement, and 
ultimately mutagenesis led to a consensus model for the lorazepam– 
GPR68 complex; this complex fit lorazepam preferentially over 
most of the decoys. Subsequently, a docking screen of 3.5 million 
commercially available molecules from ZINC59 led to a compound 
dubbed ogerin (for OGR1 ligand), a potent and selective GPR68 
PAM that has no activity for GABA or for other oGPCRs related 
to GPR68. Studies in wild-type (WT) and GPR68 knockout (KO) 
mice revealed that ogerin has on-target activity that suppresses 
contextual fear conditioning. This implies that GPR68 functions in 
brain pathways involving learning and memory45. Ogerin and an 




A similar screen has suggested that the oGPCR MRGPRX2 is an 
atypical opioid receptor, responding to drugs like morphine, codeine, 
and dextromethorphan, as well as to the endogenous opioid peptide 
dynorphin44. MRGPRX2 is expressed in mast cells and sensory neu-
rons, consistent with its role as an opioid itch receptor. To find spe-
cific chemical probes for MRGPRX2, a cycle of docking and testing 
was again deployed, leading to ZINC-72453573 (ZINC-3573; Fig. 4), 
an agonist that has no detectable activity against the four opioid 
receptors, against 316 other GPCRs, or against a panel of 97 repre-
sentative kinases. ZINC-3573 potently stimulates mast cell degranu-
lation and may be used to further probe the function of MRGPRX2. 
ZINC-3573 and an inactive stereoisomer are available as a probe pair 
for exploring MRGPRX2 biology (http://www.sigmaaldrich.com/
catalog/search?interface=All&term=(R)-ZINC-3573&N=0&focus=
product&lang=en&region=US).
Table 1 | Selected large-library docking screens against GPCRs
Target Hit rate (active/tested) Best hit ( M)
H1 histamine94 73% (19/26) 0.006
2-AR75,95 24% (6/25) 0.009
A2a adenosine96 41% (23/56) 0.032
A2a active state97 45% (9/20) (only 
antagonists found)
0.016
Dopamine D3 (ref. 98) 56% (14/25) 0.006
Dopamine D3 (allosteric)98 32% (8/25) 0.5
Dopamine D3 (ref. 41) 20% (5/25) 0.3
Dopamine D3a (ref. 41) 23% (6/26) 0.2
Dopamine D2 (ref. 77) 46% (10/21) 0.058
Muscarinic M2/M3 (ref. 76) 56% (11/19) 1.2
GLR94 8.5% (2/23) 1.9
mGlu1a (ref. 99) 14% (5/35) 10.2
5HT6a (ref. 100) 17% (6/36) 0.1
Histamine H4a (ref. 101) 18% (15/85) 8.4
A1 adenosinea 102 21% (8/39) 0.4
-opioid103 18% (4/22) 7.2
-opioid82 30% (7/23) 2.5
GPR68 (ref. 45) 33% (5/15) 10
MRGPRX2 (ref. 44) 6% (1/15) 3
aHomology model; PAM affinity not fully characterized.
Variations on this screening strategy are being investigated. In 
an empirical screen of 5,472 Riken library molecules, inverse ago-
nists for the SREB family of oGPCRs, including GPR173, were 
discovered, with affinities in the low-to-midmicromolar range60. 
These molecules were used to template the modeling of the GPR173 
structure, akin to the workflow used for GPR68 and MRGPRX2, 
although here it wasn’t used to find new ligands. A docking screen of 
10,526 in-house compounds against a homology model of GPR171 
(ref. 61) identified a dicarboxyphenyl vinyl amide, MS0015203 
(ZINC4956098; MW 249), as an orthosteric agonist61. MS0015203 
had activity in vivo in modulating feeding, which is unusual for a 
primary fragment hit. This suggests a role for GPR171 in regulating 
appetite, feeding, and perhaps metabolism.
Together, these campaigns reflect a target-based screening 
approach to deorphanization. The goal is often to develop probe 
compounds that can illuminate the biological function of the orphan 
receptors, enabling further research. Many of the tools used are 
openly accessible to the community: the PRESTO-Tango platform 
is available from ADDGENE45, and several of the docking tools and 
databases are free online9. An NIH project to deorphanize the drug-
gable genome has created resources to associate orphan receptors 
with biology and disease (http://pharos.nih.gov/idg/about).
Nonscreening- and even nontarget-based approaches to GPCR 
deorphanization are also being explored. A structural strategy, 
CoINPocket, compares ligand contact residues of the orphan recep-
tors to those of GPCRs of known activity62. When an orphan recep-
tor has an orthosteric site and modeled interacting residues similar 
to those of the ligand-annotated receptors, it may inherit the known 
ligands and interactions of those receptors. This was the case for 
the oGPCR GPR37L1. Though the endothelin receptor (ET) is the 
closest characterized receptor to GPR37L1 by sequence, neither 
endothelin peptide nor synthetic ET ligands modulate the oGPCR. 
However, the modeled structure of the GPR37L1 orthosteric site 
resembled those of the bombesin, orexin, and neuropeptide S 
(NPS) receptors, correctly suggesting that the receptor would rec-
ognize orexin and NPS ligands such as ACT-335827, JNJ-10397049, 
and SHA-68 (ref. 62). A related approach provides a structural 
context that is based on homology modeling of most of the non-
olfactory GPCRome (http://gpcrdb.org/) for pharmacophore-based 
discovery63. These homology models draw on the extensive ligand-
binding and mutagenesis information often available for GPCRs to 
provide experimental restraints for the models64. The approach has 
found new dipeptide ligands for the oGPCR GPR139 (ref. 65), sug-
gesting an endogenous ligand chemotype.
A less directed, but functionally powerful, strategy is target identi-
fication in phenotypic screens. These screens begin with compounds 
that have a cellular, or occasionally whole organism, phenotype, and 
seek the targets responsible for that activity. For instance, investiga-
tors found cyclohexylmethyl aminopyrimidines in a cell-based phe-
notypic screen for hedgehog pathway modulators. Gene expression 
analysis suggested that GPR39 might be the target, consistent with 
specific gene knockdown and ultimately on-target dose–response 
studies with optimized compounds. A role for this oGPCR in modu-
lation of the hedgehog pathway protein Gli was suggested66.
Allosteric ligands with new biology
Whereas the most obvious way that new chemotypes can confer 
novel biology is by modulating new targets, allosteric modula-
tors can do the same by acting on new sites of established targets. 
Although most drugs act tonically, allosteric modulators may be 
used to act only in the presence of an endogenous ligand, increas-
ing (PAMs) or decreasing (NAMs) native signaling (Fig. 3). One 
advantage of targeting allosteric sites is that they typically differ 
more among receptor subtypes than do orthosteric sites, enabling 
selective ligands that are otherwise challenging to find.
Among the most established allosteric targets are the muscar-
inic receptors67. Despite their long-recognized role in central ner-
vous system (CNS) disorders, muscarinic therapies for dementing 
diseases like Alzheimer’s disease have been restricted by dose-lim-
iting side effects, which are often mediated through other muscar-
inic receptor subtypes. The lower sequence identity of muscarinic 
allosteric sites has made it possible to find selective modulators. 
Leveraging the  PAM LY2033298, Conn and colleagues discovered a 
submicromolar PAM of acetylcholine, VU0152100, that was specific 
for the M4 receptor subtype68. Rounds of synthetic optimization 
led to PAMs that are more CNS penetrant and stable in vivo69 and 
that have interesting new biology, including modulation of sleep– 
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Figure 4 | Physical and docking screens to deorphanize MRGPRX2. A PRESTO-Tango screen of 8,000 drugs and reagents showed opioids as agonists of 
MRGPRX2. Receptor structure modeling followed by a large-library docking screen revealed a 0.7 M specific agonist of MRGPRX2 whose stereoisomer 
is inactive. The molecule, ZINC-3573, is active in a cell-based degranulation assay, whereas it’s stereoisomer is inactive both in signaling assays and in 
cell culture. The two molecules are openly available as a probe pair from Sigma (http://www.sigmaaldrich.com/catalog/search?interface=All&term=(R)-
ZINC-3573&N=0&focus=product&lang=en&region=US). Reprinted from ref. 44.
compound from Merck, MK-6884, is in phase I trials as a potential 
positron emission tomography (PET) ligand to assess occupancy of 
M4 PAMs in vivo (NCT02621606).
The M1 muscarinic receptor has been implicated in synaptic 
plasticity70, and M1 PAMs can enhance memory and cognition in 
animal models of Alzheimer’s disease. Here too, orthosteric ligands 
lead to dose-limiting side effects via other muscarinic subtypes. 
The M1 PAM MK-7622 is currently in phase II clinical trials for 
add-on treatment with the anticholinesterase and D4 antagonist71 
donepezil (https://clinicaltrials.gov/ct2/show/NCT01852110). Here 
again, beginning with HTS hits72, M1 PAMs were optimized for 
activity in animal models of schizophrenia. Intriguingly, and unlike 
the classic dopaminergic antipsychotics, the M1 PAMs improve 
cognition and reduce negative symptoms of psychosis in animal 
models70. The new muscarinic PAMs may act in concert with allos-
teric modulators of the metabotropic glutamate receptors, which are 
also increasingly targeted25.
New biology via well-studied orthosteric sites
As it is obvious that ligands for novel GPCRs will confer new biol-
ogy, and sensible that allosteric modulators will as well, perhaps the 
least intuitive observation has been the novel biology conferred by 
new chemotypes acting on well-explored orthosteric sites. This is 
surprising on two counts: one might not expect unrelated ligands 
to bind to the same site, and, if they did, one might think they 
would activate the same signaling pathway. There are, however, 
both empirical and theoretical reasons to expect unrelated ligands 
to bind to the same site, and signaling reasons to hope that they 
might confer new biology. Empirically, multiple unrelated classes of 
ligands have been shown to bind to the same site for multiple recep-
tors and enzymes11,73–77. Conceptually, the apparent promiscuity of 
these sites is supported by the plasticity of molecular recognition, 
whereby the same functional group can be recognized by multiple 
different environments and the same binding site can recognize 
multiple different chemotypes78. For GPCRs, with their manifold of 
active and inactive states, finding new chemotypes against the same 
site is that much more plausible. The emergence of biased signaling 
offers a framework for understanding how a new chemotype might 
bind at a well-liganded orthosteric site, stabilize one of several acti-
vated states, and activate a subset of pathways.
Biased agonists for the -opioid receptor. An early and powerful 
example of biased signaling came from the work of Bohn and Carron 
on the -opioid receptor, which is the target of morphine and other 
opioid analgesics79. Morphine analgesia was unaffected by knockout 
of the -arrestin2 protein in the mouse, but several of its side effects 
were attenuated, including respiratory depression and constipation. 
Inspired by this observation, HTS campaigns sought biased agonists 
that preferentially activated the Gi over the arrestin pathway. This 
led to the discovery of oliceridine (TRV130), a potent partial ago-
nist of Gi signaling that only slightly activates arrestinergic signaling. 
As predicted by the knockout studies, oliceridine confers analgesia 
with little respiratory depression, nausea, or constipation at analgesic 
doses. Oliceridine is a novel chemotype for the -opioid receptor, 
with its closest known ligand having an ECFP4-based Tanimoto coef-
ficient (Tc) of only 0.29, consistent with the molecule representing a 
new scaffold. Though the new biology conferred by oliceridine could 




















































































































































































































Figure 5 | Novel biased agonists for the m-opioid receptor. (a) The investigational new drug oliceridine (TRV130, left) and the lead compound PZM21 
(center) do not resemble classical agonists like morphine (right), but both confer analgesia without causing some of the dose-limiting side effects of the 
classic opioid drugs. (b) The docked pose of PZM21 in the -opioid receptor ( OR). Dashed lines represent hydrogen bond interactions and red spheres 
represent water molecules. (c) G protein (left) biased signaling vs. -arrestin biased signaling (right) of PZM21. DAMGO is a peptide agonist of the  
opioid receptor, and compound 12 is a precursor to PZM21. Error bars from replicate experiments, as described in ref. 82. (d) Mouse analgesia of PZM21 
vs. vehicle. MPE, maximum possible effect. (e) Respiratory depression conferred by PZM21, morphine, TRV130, and vehicle. Curves for PZM21 are shown 
in blue, for morphine in red, for TRV130 in green, and for vehicle in black. b–e reprinted from ref. 82.
assays for biased signaling made the recognition and optimization of 
its activity possible. Oliceridine is now in phase III clinical trials as a 
molecule to replace opioids in postoperative pain management.
Encouraged by the discovery of oliceridine80, we undertook a 
large library docking screen against the crystal structure of the 
-opioid receptor81, seeking new biased agonists. Though we could 
not expect docking to reveal subtle bias-conferring interactions, we 
hoped to find new agonist chemotypes and be able to experimentally 
select for those with biased signaling. Over 3 million commercially 
available lead-like molecules were docked, and 23 high-ranking 
molecules were selected for testing82. Seven molecules had Ki values 
ranging from 2.5 to 14 M. Though these activities were modest, 
the scaffolds were novel, and several were readily optimized. This 
rapidly led to compound PZM21 (Fig. 5), a 3.8 nM potent partial 
agonist of the -opioid receptor, activating the Gi pathway with 
little arrestinergic signaling.
Again, consistent with the -arr knockout studies79, the G-protein 
bias of PZM21 led to analgesia in a mouse model with little respira-
tory depression. Unexpectedly, this analgesia appeared to be strictly 
central, reducing affective pain without modulating reflex pain82. Just 
as surprisingly, PZM21, in contrast to classic opioids such as mor-
phine, did not provoke locomotion in a closed-field mouse assay, 
nor did it lead to reinforcing behavior in a 10-d conditioned-place 
preference assay. These unusual effects at least partially reflect the 
insistence for using novel chemotypes at the start of the campaign.
Other biased agonists with efficacy in vivo. Trevena has reported on 
TRV250, a G-protein-biased -opioid receptor agonist that has effi-
cacy against migraine and chronic pain without the serious liabilities 
of conventional delta-opioid receptor (DOR) agonists83. They have 
also reported TRV027, a new angiotensin II (ATII) agonist that is 
actually -arr biased. TRV027 improves cardiac cell survival follow-
ing acute and chronic heart failure in animals84, although a recent 
clinical trial did not meet its metrics. Meanwhile, -arr-biased D2 
agonists are being evaluated for treating schizophrenia and related 
disorders42,85, whereas G-protein-biased -opioid receptor agonists 
have favorable therapeutic actions with fewer dysphoric-like side 
effects than is typical for unbiased -opioid agonists86,87.
New opportunities for biased agonists. Biased ligands can reveal 
hidden biology in even well-established targets. Given that GPCRs 
drive multiple signaling pathways, most are candidates for such 
ligand discovery. Several of the centrally acting aminergic receptors 
stand out, including the D1 and D4 dopamine receptors, the 5HT2A 
and 5HT2C serotonin receptors, and several opioid receptor subtypes. 
For example, activation of G-protein signaling by the DRD1 (ref. 88) 
and by the DRD4 receptors has been mooted as a target for cognition 
enhancement in schizophrenia and ADHD, respectively. Similarly, 
a G-protein-biased DRD1 agonist could treat Parkinson’s disease, 
reducing dyskinetic and hypertensive effects associated with the 
arrestinergic pathway for this receptor; Pfizer has reported biased D1 
receptor agonists for this indication.
There has been a long-time interest in biased agonists for sero-
tonin receptors. Intriguingly, receptor internalization and down-
regulation by the atypical antipsychotic drug clozapine, active on 
serotonin receptors, is considered to be essential for its unique 
actions in schizophrenia89. Identifying the structural features 
responsible for clozapine’s apparent agonist activity on receptor 
internalization could lead to 5-HT2A modulators with efficacies in 
psychiatric disorders90. This is supported by the recent approval 
of the 5HT2A inverse agonist pimavanserin (http://www.fda.gov/
NewsEvents/Newsroom/PressAnnouncements/ucm498442.
htm) for treating psychosis associated with Parkinson’s disease. 
Meanwhile, at the paralogous 5-HT2C receptor, -arr interactions 
appear to be strongly modulated by agonists, RNA editing, and con-
stitutive activity91. Functional selectivity here may be responsible for 
some unique actions of antipsychotic drugs in vitro92 and of hal-
lucinogens in vivo93. As unbiased 5-HT2C agonists may have their 
therapeutic actions blunted with repeated dosing via engagement of 
the arrestin pathway (inducing desensitization, internalization, and 
receptor downregulation91), G-protein-biased agonists may yield 
compounds with therapeutic advantages.
Novel ligands conferring new GPCR pharmacology
Campaigns against new GPCRs and new allosteric sites on GPCRs 
will continue to drive the discovery of novel ligands. Acting at pre-
viously unexplored targets, or as rheostats for endogenous signal-
ing, such ligands are likely to confer new biology. Less expected is 
the return to well-precedented receptor sites with ligands that bias 
toward one of several signaling pathways that have previously been 
entangled. Though new chemotypes for these sites are not guaran-
teed to confer new biology, they often do, perhaps exploiting new 
conformations from a manifold of active and inactive GPCR states. 
The recent confluence of new signaling assays40, new crystal struc-
tures, and vast new compound libraries that may be computation-
ally interrogated for receptor fit, augurs a renaissance in GPCR 
pharmacology and chemical biology. 
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